A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)

Trial Profile

A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Capmatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms Geometry Mono-1
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 18 Mar 2018 Planned number of patients changed from 399 to 429.
    • 07 Feb 2018 Planned primary completion date changed from 4 Sep 2018 to 5 Sep 2018.
    • 18 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top